Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00770536
First received: October 9, 2008
Last updated: October 9, 2014
Last verified: September 2014
  Purpose

This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion.

It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer.


Condition Intervention Phase
Cancer
Carcinoma
Fallopian Tube Cancer
Gynecological Malignancies
Metastases
Oncology
Ovarian Cancer
Solid Tumors
Tumors
Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
Drug: B1: AMG 386 10 mg/kg + Topotecan
Drug: B3: AMG 386 15mg/kg + Topotecan
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • The primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan [ Time Frame: first 4 weeks of treatment ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the treatment effect as measured by: objective response rate (ORR), duration of response (DOR), PFS, change in tumor burden, CA 125 Response and Progression by GCIG and CA-125 duration of response [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: No ]
  • To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs. [ Time Frame: first 4 weeks of treatment ] [ Designated as safety issue: Yes ]
  • To determine the pharmacokinetics of pegylated liposomal doxorubicin (and its metabolite, doxorubicinol), topotecan and AMG 386 (Cmax, AUC, and Cmin for intensive assessment; Cmax and Cmin for sparse assessment). [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: No ]
  • To estimate the incidence of anti AMG 386 antibody formation. [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: Yes ]

Enrollment: 103
Study Start Date: January 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part 1
In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
Other Names:
  • Liposomal doxorubicin
  • AMG 386
Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
Other Names:
  • AMG 386
  • Liposomal doxorubicin
Drug: B1: AMG 386 10 mg/kg + Topotecan
B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
Other Names:
  • Topotecan
  • AMG 386
Drug: B3: AMG 386 15mg/kg + Topotecan
AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
Other Names:
  • AMG 386
  • Topotecan
Experimental: Part 2
The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
Other Names:
  • Liposomal doxorubicin
  • AMG 386
Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
Other Names:
  • AMG 386
  • Liposomal doxorubicin
Drug: B1: AMG 386 10 mg/kg + Topotecan
B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
Other Names:
  • Topotecan
  • AMG 386
Drug: B3: AMG 386 15mg/kg + Topotecan
AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
Other Names:
  • AMG 386
  • Topotecan

Detailed Description:

The purpose of this study is to evaluate the effectiveness and safety of AMG 386 when used with pegylated liposomal doxorubicin or topotecan in subjects with advanced recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically documented recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • Subjects must have received at least one platinum containing regimen
  • Radiographically documented progression per RECIST criteria with modifications or progression of CA 125 as adopted by GCIG during or subsequent to the last chemotherapy regimen
  • Subjects may include those with measurable or non measurable disease
  • All scans and x-rays used to document measurable or non measurable disease must be done within 28 days prior to enrollment
  • Female 18 years of age or older at the time the written informed consent is obtained
  • GOG Performance Status of 0 or 1
  • Left Ventricular Ejection Fraction (LVEF) >= institutional lower limit of normal for subjects assigned to cohort A only
  • Adequate organ function as assessed by laboratory studies (hematological and chemistries)
  • Life expectancy >= 3 months (per investigator opinion)
  • Subjects of child bearing potential who have not undergone a bilateral salpingo oophorectomy and are sexually active must consent to use an accepted and effective double barrier non hormonal method of contraception from signing the informed consent through 6 months after last dose of study drug

Exclusion Criteria:

  • Subjects believed to be a higher than average risk of bowel perforation. This includes symptoms of partial or complete bowel obstruction, recent (within 6 months) history of fistula or bowel perforation, subjects requiring total parenteral nutrition and continuous hydration
  • Previous abdominal /or pelvic external beam radiotherapy
  • Known history of central nervous system metastases
  • Subjects with a history of prior malignancy, except:

    • Malignancy treated with curative intent and with no known active disease present for >= 3 years before study day 1 and felt to be at low risk for recurrence by treating physician
    • Adequately treated non melanomatous skin cancer or lentigo maligna without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
  • Prior myeloablative high dose chemotherapy with allogeneic or autologous stem cell (or bone marrow) transplant
  • History of arterial or deep venous thromboembolism within 12 months prior to enrollment
  • Clinically significant cardiac disease within 12 months prior to enrollment
  • Prior treatment with doxorubicin or pegylated liposomal doxorubicin (cohort A subjects) and topotecan (cohort B subjects)
  • Current or within 30 days prior to enrollment treatment with immune modulators such as systemic cyclosporine and tacrolimus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00770536

Locations
United States, Arizona
Research Site
Tucson, Arizona, United States, 85724-5024
United States, California
Research Site
Sacramento, California, United States, 95817
United States, Florida
Research Site
Orlando, Florida, United States, 32806
Research Site
Tampa, Florida, United States, 33612
United States, Minnesota
Research Site
St. Louis Park, Minnesota, United States, 55426
United States, North Carolina
Research Site
Winston Salem, North Carolina, United States, 27103
United States, North Dakota
Research Site
Bismarck, North Dakota, United States, 58501
United States, Ohio
Research Site
Columbus, Ohio, United States, 43219
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19111
Australia, South Australia
Research Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Research Site
Footscray, Victoria, Australia, 3011
Research Site
Parkville, Victoria, Australia, 3050
Belgium
Research Site
Leuven, Belgium, 3000
Research Site
Liège, Belgium, 4000
Research Site
Liège, Belgium, 4000
Research Site
Wilrijk, Belgium, 2610
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT00770536     History of Changes
Other Study ID Numbers: 20070182
Study First Received: October 9, 2008
Last Updated: October 9, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
United States: Western Institutional Review Board

Keywords provided by Amgen:
fallopian tube cancer
Gynecological Malignancy
primary peritoneal cancer of predominantly epithelial origin
Stage II to IV ovarian cancer

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Neoplasms
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Doxorubicin
Liposomal doxorubicin
Topotecan
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on November 25, 2014